Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials

[1] Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34

[2] Miller KD(2017)Breast cancer The Lancet 389 1134-1150

[3] Jemal A(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials The Lancet 386 1341-1352

[4] Harbeck N(2019)Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure Int J Cancer 145 274-283

[5] Gnant M(2017)Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications Breast Cancer 25 379-391

[6] Van Hellemond IEG(2018)Fulvestrant for the treatment of advanced breast cancer Expert Rev Anticancer Ther 18 619-628

[7] Vriens IJH(2018)Fulvestrant in management of hormone receptor-positive metastatic breast cancer Future Oncol 14 1789-1800

[8] Peer PGM(2017)Fulvestrant for hormone-sensitive metastatic breast cancer Cochrane Database Syst Rev. 1 CD011093-29

[9] Swinkels ACP(2019)Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials Front Oncol 9 510-1925

[10] Smorenburg CH(2017)A review of fulvestrant in breast cancer Oncol Ther 5 17-444

[1] Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34

[2] Miller KD(2017)Breast cancer The Lancet 389 1134-1150

[3] Jemal A(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials The Lancet 386 1341-1352

[4] Harbeck N(2019)Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure Int J Cancer 145 274-283

[5] Gnant M(2017)Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications Breast Cancer 25 379-391

[6] Van Hellemond IEG(2018)Fulvestrant for the treatment of advanced breast cancer Expert Rev Anticancer Ther 18 619-628

[7] Vriens IJH(2018)Fulvestrant in management of hormone receptor-positive metastatic breast cancer Future Oncol 14 1789-1800

[8] Peer PGM(2017)Fulvestrant for hormone-sensitive metastatic breast cancer Cochrane Database Syst Rev. 1 CD011093-29

[9] Swinkels ACP(2019)Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials Front Oncol 9 510-1925

[10] Smorenburg CH(2017)A review of fulvestrant in breast cancer Oncol Ther 5 17-444